Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction

W. Armstrong, Paul; S.P. Lam, Carolyn; J. Anstrom, Kevin; A. Ezekowitz, Justin; F. Hernandez, Adrian; M. O’Connor, Christopher; Pieske, Burkert; Ponikowski, Piotr; J. Shah, Sanjiv; D. Solomon, Scott; A. Voors, Adriaan; She, Lilin; Vlajnic, Vanja; Carvalho, Francine; Bamber, Luke; O. Blaustein, Robert; Roessig, Lothar; Butler, Javed; Study Group, VITALITY-HFpEF

doi:10.1001/jama.2020.15922

Public

Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction

Published in JAMA • Oct 20, 2020

Authors:

Paul W. Armstrong

Carolyn S.P. Lam

Kevin J. Anstrom

Abstract

Importance: Patients with heart failure and preserved ejection fraction (HFpEF) are at high risk of mortality, hospitalizations, and reduced functional capacity and quality of life. Objective: To assess the efficacy of the oral soluble guanylate cyclase stimulator vericiguat on the physical limitati...

Subject

Medicine

Ejection fraction

Heart failure

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!